Results 41 to 50 of about 4,863 (192)

Hepcidin antagonists for potential treatments of disorders with hepcidin excess [PDF]

, 2014
5noThe discovery of hepcidin clarified the basic mechanism of the control of systemic iron homeostasis. Hepcidin is mainly produced by the liver as a propeptide and processed by furin into the mature active peptide.
Maria Regoni, Maura Poli, Michela Asperti, Paola Ruzzenenti, Paolo Arosio   +4 more
core   +2 more sources

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling

Frontiers in Immunology, 2022
BackgroundDysregulated interleukin (IL)-6 production can be characterised by the levels present, the kinetics of its rise and its inappropriate location. Rapid, excessive IL-6 production can exacerbate tissue damage in vital organs.
Jean-François Rossi, Jean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C. Fajgenbaum, David C. Fajgenbaum, Bernard Klein   +9 more
doaj   +1 more source

Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B-cell acute lymphoblastic leukaemia. [PDF]

Br J Haematol
British Journal of Haematology, Volume 207, Issue 4, Page 1673-1678, October 2025.
Rankin AW, Silbert SK, Duncan BB, Yates B, Nath A, Biassou N, Suffredini AF, Danner RL, Natanson C, Ahluwalia AK, Little L, Foley T, Murthy HS, Shalabi H, Nyquist P, Shah NN.   +15 more
europepmc   +2 more sources

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. [PDF]

, 2020
BACKGROUND:Siltuximab is recommended by international consensus as a first-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety data.
Casper, Corey, Fayad, Luis E, Gibson, Damilola, Kanhai, Karan, Kurzrock, Razelle, van Rhee, Frits, Voorhees, Peter M   +6 more
core  

Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]

, 2019
Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C, Duan, Zhenfeng, Feng, Wenlong, Hornicek, Francis J, Shi, Huirong   +4 more
core   +2 more sources

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis [PDF]

, 2016
Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M.
Dodoo, E, Maeurer, M, Rao, M, Zumla, A
core   +1 more source

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

Xiehe Yixue Zazhi, 2023
Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by ...
ZHANG Lu, LI Jian
doaj   +1 more source

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. [PDF]

J Clin Pharmacol
Abstract Idecabtagene vicleucel (ide‐cel, ABECMA) is an autologous, B‐cell maturation antigen‐directed, chimeric antigen receptor (CAR) T‐cell therapy, which has demonstrated significantly improved progression‐free survival (PFS) and overall response rate (ORR) in patients with triple‐class‐exposed relapsed/refractory multiple myeloma (TCE RRMM). Here,
Wu F, Zheng X, Burnett J, Masilamani M, Zhang W, Zhong X, Caia A, Cook M, Piasecki J, Kondic A, Lamba M, Zhou J.   +11 more
europepmc   +2 more sources

Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel

HemaSphere, 2023
Castleman disease describes a group of heterogeneous clinicopathological disorders now included in the tumor-like lesions with B-cell predominance of the World Health Organization classification.
Pier Luigi Zinzani, Marco Paulli, Luca Arcaini, Emanuel Della Torre, Simone Ferrero, Amalia Figuera, Ferdinando Frigeri, Maurizio Martelli, Elena Sabattini, Riccardo Scarpa, Giovanni Barosi   +10 more
doaj   +1 more source

Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma [PDF]

, 2014
Thrombocytosis portends adverse prognostic significance in many types of cancers including ovarian and lung carcinoma. In this study, we determined the prevalence and prognostic significance of thrombocytosis (defined as platelet count in excess of 400 ×
Guo, Tianhua, Krzystanek, Marcin, Szallasi, Arpad, Szallasi, Zoltan   +3 more
core   +4 more sources